Clinical Research in Southampton
Southampton Children's Hospital

A A A Text only | Accessibility | Privacy and cookies

Home
About the Trust
Our services
Patients and visitors
Our hospitals
Education
Research
Working here
Contact us

Browse site A to Z

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Search results

Go To Advanced Search

Search

You could also try: trouble (31), riot (2), disorder (273)

EC-DPH IV (Cyclophosphamide-Epirubicin-Docetaxel-Pertuzumab-Trastuzumab IV)

Description: Please refer to the most up to date Bluteq eligibility criteria for pertuzumab and trastuzumab before prescribing.
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Breastcancer/EC-DPH-IV-Cyclophosphamide-Epirubicin-Docetaxel-Pertuzumab-Trastuzumab-IV.pdf

AmB - Brexucel - Cyclophosphamide (500) - Fludarabine (30)

Description: Chemotherapy Protocol CHIMERIC ANTIGEN RECEPTOR T-CELL (CAR-T) THERAPY Mantle Cell lymphoma (MCL) AmB – BREXUCEL – CYCLOPHOSPHAMIDE (500) – FLUDARABINE (30) Ambulatory
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/AmB-Brexucel-Cyclophosphamide-500-Fludarabine-30-Ver-1.pdf

AmB LEAM (split)-Lomustine-Cytarabine-Etoposide-Melphalan

Description: Chemotherapy Protocol LYMPHOMA LOMUSTINE-CYTARABINE-ETOPOSIDE (split)-MELPHALAN (LEAM) Ambulatory Regimen This regimen is for AMBULATORY CARE pathway use only and
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/AmB-LEAM-split-Lomustine-Cytarabine-Etoposide-Melphalan.pdf

Avelumab-Axitinib

Description: Chemotherapy Protocol RENAL CELL AVELUMAB-AXITINIB Regimen • Renal Cell - Avelumab-Axitinib Indication • Unresectable locally advanced or metastatic renal cell carcinoma (RCC
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Renal-cell/Axitinib-Avelumab.pdf

Carboplatin(AUC6)-Paclitaxel-Pembrolizumab

Description: Chemotherapy Protocol LUNG CANCER CARBOPLATIN (AUC6)-PACLITAXEL-PEMBROLIZUMAB Regimen • Lung-Carboplatin (AUC6)-Paclitaxel-Pembrolizumab Indication - The patient has a histologically- or
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-non-small-cellNSCLC/CarboplatinAUC6-Paclitaxel-Pembrolizumab.pdf

UHS AR 22-23-6

Description: 2022/23 Incorporating the quality account University Hospital Southampton NHS Foundation Trust Annual Report and Accounts 2022/23 Presented to Parliament
Url: /Media/UHS-website-2019/Docs/About-the-Trust/Annual-reports-and-quality-accounts/UHS-AR-22-23-6.pdf

Transient ischemic attack (TIA) - patient information

Description: Transient ischemic attack (TIA) Information for patients You have been given this booklet because you have been referred to the TIA
Url: /Media/UHS-website-2019/Patientinformation/Brain-and-spine/Transient-ischemic-attack-TIA-685-PIL.pdf

Cytarabine(SC)-Venetoclax

Description: Chemotherapy Protocol Acute Myeloid Leukaemia CYTARABINE (SC) - VENETOCLAX Regimen  AML – Cytarabine (SC) -Venetoclax Indication  Newly diagnosed acute myeloid leukaemia (AML).  Patient
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/AML/CytarabineSC-Venetoclax.pdf

Atezolizumab-Bevacizumab

Description: Chemotherapy Protocol Hepatocellular Cancer ATEZOLIZUMAB-BEVACIZUMAB Regimen  HCC-Atezolizumab-Bevacizumab Indication  Atezolizumab in combination with bevacizumab for the first-line systemic
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Hepatobiliary/Atezolizumab-Bevacizumab.pdf

Ipilimumab(1mg/kg)-Nivolumab(3mg/kg)

Description: Chemotherapy Protocol RENAL CANCER IPILIMUMAB (1mg/kg)-NIVOLUMAB(3mg/kg) Regimen • Renal – Ipilimumab (1mg/kg)-Nivolumab (3mg/kg) Indication • Ipilimumab in
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Renal-cell/Ipilimumab1mgkg-Nivolumab3mgkg.pdf

261 to 270 of 282

Previous … 25 26 27 28 29 Next